Research Analysts Issue Forecasts for OCUL FY2026 Earnings

Ocular Therapeutix, Inc. (NASDAQ:OCUL) – Investment analysts at HC Wainwright decreased their FY2026 earnings estimates for shares of Ocular Therapeutix in a research note issued to investors on Tuesday, November 10th. HC Wainwright analyst Y. Chen now anticipates that the biopharmaceutical company will earn ($1.62) per share for the year, down from their prior forecast of ($1.49). HC Wainwright currently has a “Buy” rating and a $28.00 price target on the stock. The consensus estimate for Ocular Therapeutix’s current full-year earnings is ($1.49) per share. HC Wainwright also issued estimates for Ocular Therapeutix’s Q4 2026 earnings at ($0.46) EPS, Q1 2027 earnings at ($0.47) EPS, Q2 2027 earnings at ($0.47) EPS, Q3 2027 earnings at ($0.47) EPS, Q4 2027 earnings at ($0.46) EPS and FY2027 earnings at ($1.87) EPS.

Ocular Therapeutix (NASDAQ:OCUL) last posted its earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.06). Ocular Therapeutix had a negative return on equity of 56.26% and a negative net margin of 648.64%. The business had revenue of $12.87 million for the quarter, compared to the consensus estimate of $14.27 million. During the same quarter in the prior year, the firm posted ($0.38) earnings per share. The business’s revenue was down 11.5% on a year-over-year basis.

Several other research firms have also recently weighed in on OCUL. Wall Street Zen raised Ocular Therapeutix from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $18.00 target price on shares of Ocular Therapeutix in a report on Monday, October 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ocular Therapeutix in a research report on Thursday, October 15th. Chardan Capital reaffirmed a “buy” rating and issued a $23.00 target price on shares of Ocular Therapeutix in a research report on Friday, October 2nd. Finally, Royal Bank Of Canada reiterated an “outperform” rating on shares of Ocular Therapeutix in a research report on Tuesday, September 29th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $23.83.

Ocular Therapeutix Trading Up 0.8%

Ocular Therapeutix stock opened at $6.66 on Thursday. The company has a current ratio of 13.10, a quick ratio of 13.03 and a debt-to-equity ratio of 0.14. Ocular Therapeutix has a twelve month low of $6.00 and a twelve month high of $16.44. The company has a 50 day moving average of $8.17 and a 200-day moving average of $8.96.

Insiders Place Their Bets

In other news, insider Pravin Dugel sold 21,649 shares of Ocular Therapeutix stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $10.77, for a total transaction of $233,159.73. Following the sale, the insider directly owned 2,525,429 shares of the company’s stock, valued at approximately $27,198,870.33. This trade represents a 0.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Peter Kaiser sold 9,990 shares of Ocular Therapeutix stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $7.05, for a total transaction of $70,429.50. Following the sale, the insider owned 254,388 shares in the company, valued at approximately $1,793,435.40. This represents a 3.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 98,090 shares of company stock worth $787,920 over the last 90 days. Insiders own 3.10% of the company’s stock.

Institutional Trading of Ocular Therapeutix

Institutional investors have recently modified their holdings of the business. Private Advisor Group LLC bought a new position in shares of Ocular Therapeutix during the third quarter worth about $130,000. CenterBook Partners LP acquired a new position in shares of Ocular Therapeutix during the third quarter valued at about $233,000. Kraematon Investment Advisors Inc. boosted its holdings in Ocular Therapeutix by 6.9% in the third quarter. Kraematon Investment Advisors Inc. now owns 117,517 shares of the biopharmaceutical company’s stock worth $901,000 after acquiring an additional 7,550 shares in the last quarter. Commonwealth Equity Services LLC lifted its holdings in shares of Ocular Therapeutix by 8.1% in the 3rd quarter. Commonwealth Equity Services LLC now owns 20,992 shares of the biopharmaceutical company’s stock worth $161,000 after purchasing an additional 1,575 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Ocular Therapeutix in the third quarter valued at $86,000. Institutional investors own 59.21% of the company’s stock.

Trending Headlines about Ocular Therapeutix

These are some of the OCUL headlines that stood out recently:

• Positive Sentiment: HC Wainwright raised its price target to $28 from $25 and reiterated its Buy rating, signaling substantial upside in the analyst’s view. Ocular Therapeutix Stock Gets Price Target Increase from HC Wainwright
• Positive Sentiment: Recent coverage highlighted Phase 3 success in wet age-related macular degeneration, a potential catalyst for Ocular’s AXPAXLI program and investor optimism. Investors Reacting to Ocular Therapeutix Phase 3 Wet AMD Success
• Neutral Sentiment: Commentary noted that the Phase 3 results have not ended debate over the company’s valuation, so the clinical progress may be weighed against execution and commercial prospects. Ocular Therapeutix on Phase 3 AMD Win and Valuation Debate

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for eye diseases and conditions. Based in Bedford, Massachusetts, the company uses its proprietary hydrogel-based technology to deliver medicines to the eye over time. Its marketed product, DEXTENZA, is a corticosteroid insert placed in the tear duct by an eye-care professional to treat inflammation and pain following ophthalmic surgery. Ocular Therapeutix also develops investigational therapies for retinal diseases and other eye conditions, including treatments designed for sustained drug delivery.